{"id":"https://openalex.org/W7225756423","doi":"https://doi.org/10.64898/2026.11.08.26367556","title":"OVM-200, a recombinant overlapping peptide vaccine, breaks immune tolerance to survivin in patients with advanced solid tumours: a multicentre, open-label, dose-expansion, phase 1 study","display_name":"OVM-200, a recombinant overlapping peptide vaccine, breaks immune tolerance to survivin in patients with advanced solid tumours: a multicentre, open-label, dose-expansion, phase 1 study","publication_year":2026,"publication_date":"2026-11-10","ids":{"openalex":"https://openalex.org/W7225756423","doi":"https://doi.org/10.64898/2026.11.08.26367556"},"language":"en","primary_location":{"id":"doi:10.64898/2026.11.08.26367556","doi":"https://doi.org/10.64898/2026.11.08.26367556","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.11.08.26367556","pdf_url":null,"source":{"id":"https://openalex.org/S3005729997","display_name":"medRxiv","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310315909"],"host_organization_lineage_names":["Cold Spring Harbor Laboratory Press"],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"medRxiv","raw_type":"posted-content"},"volume":null,"type":"preprint","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://doi.org/10.64898/2026.11.08.26367556","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5076745657","display_name":"Peter Kok-Ting Wan","orcid":"https://orcid.org/0000-0003-0414-5453","observed_orcids":["https://orcid.org/0000-0003-0414-5453"]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Peter Kok-Ting Wan","raw_affiliation_strings":["University of Oxford;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Oxford;","institution_ids":["https://openalex.org/I40120149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5121390536","display_name":"Thomas Morris","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thomas Morris","raw_affiliation_strings":["Oxford Vacmedix;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oxford Vacmedix;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101947656","display_name":"Martin F\u00f6rster","orcid":"https://orcid.org/0000-0002-0744-9834","observed_orcids":["https://orcid.org/0000-0002-0744-9834"]},"institutions":[{"id":"https://openalex.org/I1340918713","display_name":"University College London Hospitals NHS Foundation Trust","ror":"https://ror.org/042fqyp44","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1340918713"]},{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Martin Forster","raw_affiliation_strings":["University College London Hospitals NHS Trust;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University College London Hospitals NHS Trust;","institution_ids":["https://openalex.org/I1340918713","https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5161052886","display_name":"Tianen Zhang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Tianen Zhang","raw_affiliation_strings":["University of Oxford;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Oxford;","institution_ids":["https://openalex.org/I40120149"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5126198717","display_name":"Michael J. Flynn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1340918713","display_name":"University College London Hospitals NHS Foundation Trust","ror":"https://ror.org/042fqyp44","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1340918713"]},{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Michael Flynn","raw_affiliation_strings":["University College London Hospitals NHS Trust;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University College London Hospitals NHS Trust;","institution_ids":["https://openalex.org/I1340918713","https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038964768","display_name":"Florence Chamberlain","orcid":"https://orcid.org/0000-0001-7583-1341","observed_orcids":["https://orcid.org/0000-0001-7583-1341"]},"institutions":[{"id":"https://openalex.org/I1340918713","display_name":"University College London Hospitals NHS Foundation Trust","ror":"https://ror.org/042fqyp44","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1340918713"]},{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Florence Chamberlain","raw_affiliation_strings":["University College London Hospitals NHS Trust;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University College London Hospitals NHS Trust;","institution_ids":["https://openalex.org/I1340918713","https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038957218","display_name":"Mark H. Tuthill","orcid":"https://orcid.org/0000-0002-2099-5709","observed_orcids":["https://orcid.org/0000-0002-2099-5709"]},"institutions":[{"id":"https://openalex.org/I4210147381","display_name":"Oxford University Hospitals NHS Trust","ror":"https://ror.org/03h2bh287","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210147381"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Mark Tuthill","raw_affiliation_strings":["Oxford University Hospitals NHS Trust;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oxford University Hospitals NHS Trust;","institution_ids":["https://openalex.org/I4210147381"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020696914","display_name":"Fiona C. Thistlethwaite","orcid":"https://orcid.org/0000-0002-4832-7008","observed_orcids":["https://orcid.org/0000-0002-4832-7008"]},"institutions":[{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Fiona Thistlethwaite","raw_affiliation_strings":["The Christie NHS Foundation Trust;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Christie NHS Foundation Trust;","institution_ids":["https://openalex.org/I4210133995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068416680","display_name":"Anja Williams","orcid":"https://orcid.org/0000-0002-4944-1558","observed_orcids":["https://orcid.org/0000-0002-4944-1558"]},"institutions":[{"id":"https://openalex.org/I172427033","display_name":"Sarah Cannon Research Institute","ror":"https://ror.org/03cp5cj42","country_code":"GB","type":"education","lineage":["https://openalex.org/I172427033"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Anja Williams","raw_affiliation_strings":["Sarah Cannon Research Institute"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute","institution_ids":["https://openalex.org/I172427033"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086832703","display_name":"William Finch","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William Finch","raw_affiliation_strings":["Oxford Vacmedix;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oxford Vacmedix;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159734591","display_name":"Wenshu Lu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Wenshu Lu","raw_affiliation_strings":["University of Oxford;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Oxford;","institution_ids":["https://openalex.org/I40120149"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5161404962","display_name":"Shisong Jiang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40120149","display_name":"University of Oxford","ror":"https://ror.org/052gg0110","country_code":"GB","type":"education","lineage":["https://openalex.org/I40120149"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Shisong Jiang","raw_affiliation_strings":["University of Oxford;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Oxford;","institution_ids":["https://openalex.org/I40120149"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C2779053233","wikidata":"https://www.wikidata.org/wiki/Q731235","display_name":"ELISPOT","level":4,"score":0.7588000297546387},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7332000136375427},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6899999976158142},{"id":"https://openalex.org/C2775975398","wikidata":"https://www.wikidata.org/wiki/Q906904","display_name":"Survivin","level":3,"score":0.61080002784729},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5839999914169312},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5552999973297119},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5058000087738037},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5023999810218811},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.5023000240325928},{"id":"https://openalex.org/C22070199","wikidata":"https://www.wikidata.org/wiki/Q192995","display_name":"Vaccination","level":2,"score":0.4828000068664551},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.46540001034736633},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.423799991607666},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.4081999957561493},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.38580000400543213},{"id":"https://openalex.org/C2776789287","wikidata":"https://www.wikidata.org/wiki/Q7166532","display_name":"Peptide vaccine","level":4,"score":0.3781000077724457},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.35280001163482666},{"id":"https://openalex.org/C40767141","wikidata":"https://www.wikidata.org/wiki/Q285697","display_name":"Recombinant DNA","level":3,"score":0.34779998660087585},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.33980000019073486},{"id":"https://openalex.org/C195616568","wikidata":"https://www.wikidata.org/wiki/Q128711","display_name":"Epitope","level":3,"score":0.3052999973297119},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.3021000027656555},{"id":"https://openalex.org/C141341695","wikidata":"https://www.wikidata.org/wiki/Q2368661","display_name":"Surrogate endpoint","level":2,"score":0.30090001225471497},{"id":"https://openalex.org/C2779281246","wikidata":"https://www.wikidata.org/wiki/Q172847","display_name":"Peptide","level":2,"score":0.29649999737739563},{"id":"https://openalex.org/C2779616870","wikidata":"https://www.wikidata.org/wiki/Q4677560","display_name":"Active immunotherapy","level":4,"score":0.2939000129699707},{"id":"https://openalex.org/C2777702733","wikidata":"https://www.wikidata.org/wiki/Q1356761","display_name":"Immune tolerance","level":3,"score":0.2906999886035919},{"id":"https://openalex.org/C3017875465","wikidata":"https://www.wikidata.org/wiki/Q189146","display_name":"Cellular immunity","level":3,"score":0.28450000286102295},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.2777000069618225},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.2522999942302704}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.64898/2026.11.08.26367556","doi":"https://doi.org/10.64898/2026.11.08.26367556","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.11.08.26367556","pdf_url":null,"source":{"id":"https://openalex.org/S3005729997","display_name":"medRxiv","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310315909"],"host_organization_lineage_names":["Cold Spring Harbor Laboratory Press"],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"medRxiv","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.64898/2026.11.08.26367556","doi":"https://doi.org/10.64898/2026.11.08.26367556","is_oa":true,"landing_page_url":"https://doi.org/10.64898/2026.11.08.26367556","pdf_url":null,"source":{"id":"https://openalex.org/S3005729997","display_name":"medRxiv","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":["https://openalex.org/P4310315909"],"host_organization_lineage_names":["Cold Spring Harbor Laboratory Press"],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"medRxiv","raw_type":"posted-content"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Survivin":[0],"(BIRC5)":[1],"is":[2,12,23],"broadly":[3],"overexpressed":[4],"in":[5,88,108,163,249],"human":[6],"cancers":[7],"but,":[8],"as":[9],"a":[10,24,49,199],"self-antigen,":[11],"subject":[13],"to":[14,41,104,198,211,287],"immune":[15,285],"tolerance":[16,286],"that":[17,281],"limits":[18],"spontaneous":[19,160],"antitumour":[20,126],"immunity.":[21,178],"OVM-200":[22,91,179,269],"recombinant":[25],"overlapping":[26],"peptide":[27],"vaccine":[28],"spanning":[29],"full-length":[30],"survivin,":[31],"with":[32,67,102,140,165,188,254,264],"cathepsin":[33],"S-cleavable":[34],"linker":[35],"sequences":[36],"inserted":[37],"between":[38],"adjacent":[39],"peptides":[40],"enhance":[42],"antigen":[43],"processing":[44],"and":[45,82,118,125,185,203,227,273,290],"presentation.":[46],"OVM-200-100":[47],"was":[48,92,116,131,245,270],"multicentre,":[50],"open-label":[51],"phase":[52,80,89],"1":[53],"study":[54],"conducted":[55],"at":[56,85,196],"4":[57],"UK":[58],"sites.":[59],"The":[60,113],"pooled":[61],"2,000-\u03bcg":[62],"cohort":[63],"comprised":[64],"27":[65],"patients":[66,78,109,164,251],"advanced":[68],"non-small":[69],"cell":[70,230],"lung,":[71],"ovarian":[72],"or":[73,152],"prostate":[74],"cancer,":[75],"including":[76],"24":[77,238],"from":[79,194,209],"1b":[81],"3":[83,99],"treated":[84],"this":[86],"dose":[87],"1a.":[90],"administered":[93],"subcutaneously":[94],"every":[95],"2":[96],"weeks":[97],"for":[98],"initial":[100],"vaccinations,":[101],"up":[103],"8":[105],"additional":[106],"doses":[107],"deriving":[110],"clinical":[111,279],"benefit.":[112],"primary":[114],"endpoint":[115],"safety":[117],"tolerability,":[119],"secondary":[120],"endpoints":[121],"included":[122],"survivin-specific":[123,177,276],"immunogenicity,":[124],"activity":[127],"by":[128],"RECIST":[129],"v1.1":[130],"exploratory.":[132],"OVM-200-related":[133],"adverse":[134,145,150],"events":[135,151],"were":[136],"exclusively":[137],"grade":[138,143],"1-2,":[139],"no":[141],"treatment-related":[142],"\u22653":[144],"events,":[146],"dose-limiting":[147],"toxicities,":[148],"serious":[149],"deaths.":[153],"A":[154],"systematic":[155],"literature":[156],"analysis":[157],"showed":[158],"low":[159,175],"anti-survivin":[161,190,224,259],"seroreactivity":[162],"cancer.":[166],"In":[167],"our":[168],"cohort,":[169],"pretreatment":[170],"tumours":[171],"expressed":[172],"survivin":[173,289],"despite":[174],"baseline":[176,197],"vaccination":[180],"subsequently":[181],"induced":[182,274],"robust":[183,275],"humoral":[184],"cellular":[186],"responses,":[187],"median":[189,204],"IgG":[191],"titres":[192,226,261],"increasing":[193,208],"20":[195],"peak":[200],"of":[201],"81,920":[202],"interferon-\u03b3":[205],"ELISpot":[206],"responses":[207,231],"16.7":[210],"504.6":[212],"spot-forming":[213],"units":[214],"per":[215],"10\u2076":[216],"PBMCs.":[217],"Patients":[218,253],"receiving":[219,234],"\u22654":[220],"vaccinations":[221],"developed":[222],"higher":[223,258],"antibody":[225,260],"stronger":[228],"T":[229],"than":[232,262],"those":[233,263],"fewer":[235],"doses.":[236],"Among":[237],"RECIST-evaluable":[239],"patients,":[240],"the":[241],"best":[242],"overall":[243],"response":[244],"stable":[246],"disease":[247,266],"(SD)":[248],"6":[250],"(25%).":[252],"SD":[255],"had":[256],"significantly":[257],"progressive":[265],"(PD)":[267],"(p=0.0418).":[268],"well":[271],"tolerated":[272],"immunity,":[277],"providing":[278],"evidence":[280],"it":[282],"can":[283],"break":[284],"self-antigen":[288],"supporting":[291],"further":[292],"development.":[293],"ClinicalTrials.gov":[294],"identifier:":[295],"NCT05104515":[296],".":[297]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-11T00:00:00"}